Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aptinyx Inc. (APTX)

0.259   -0.013 (-4.81%) 12-02 16:00
Open: 0.2673 Pre. Close: 0.2721
High: 0.2723 Low: 0.2513
Volume: 239,426 Market Cap: 18(M)

Technical analysis

as of: 2022-12-02 4:20:56 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.38     One year: 0.45
Support: Support1: 0.23    Support2: 0.19
Resistance: Resistance1: 0.32    Resistance2: 0.38
Pivot: 0.29
Moving Average: MA(5): 0.27     MA(20): 0.29
MA(100): 0.4     MA(250): 1.29
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 20.2     %D(3): 26.3
RSI: RSI(14): 39.9
52-week: High: 3.75  Low: 0.2
Average Vol(K): 3-Month: 240 (K)  10-Days: 93 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ APTX ] has closed above bottom band by 14.0%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.27 - 0.27 0.27 - 0.28
Low: 0.25 - 0.25 0.25 - 0.25
Close: 0.26 - 0.26 0.26 - 0.26

Company Description

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Headline News

Fri, 02 Dec 2022
The most innovative headphones of 2022 - Digital Trends

Tue, 29 Nov 2022
AptX Adaptive vs. aptX HD vs. LDAC: Which Bluetooth codec is the best? - Digital Trends

Thu, 24 Nov 2022
Apple clarifies lack of high-definition Bluetooth codec support for AirPods Max and AirPods Pro 2 - Notebookcheck.net

Wed, 23 Nov 2022
Bose QuietComfort Earbuds II to soon receive Qualcomm aptX Lossless support - gizmochina

Sun, 20 Nov 2022
Creative BT-W3 and BT-W4 – add Qualcomm aptX and Hi-Def sound to your computer or smartphone (review) - CyberShack

Sat, 19 Nov 2022
What is aptX? Cutting through the clutter of Qualcomm’s codecs - Digital Trends

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 68 (M)
Shares Float 39 (M)
% Held by Insiders 12.1 (%)
% Held by Institutions 45.9 (%)
Shares Short 326 (K)
Shares Short P.Month 151 (K)

Stock Financials

EPS -1.2
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.72
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -42.1
Return on Equity (ttm) -90.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.81
Sales Per Share 0
EBITDA (p.s.) -1.04
Qtrly Earnings Growth 0
Operating Cash Flow -68 (M)
Levered Free Cash Flow -40 (M)

Stock Valuations

PE Ratio -0.22
PEG Ratio 0
Price to Book value 0.35
Price to Sales 0
Price to Cash Flow -0.26

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.